The experimental design includes in vivo administration of ginsenoside Rb1 to cardiac-specific Twist1-overexpressing HF rat models, and in vitro treatment of Twist1-overexpressing cardiomyocytes with ginsenoside Rb1 to verify its regulatory role in HF pathogenesis. This evidence concerns the gene TWIST1 and hydrops fetalis.